Published in Cancer Res on January 15, 1996
Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci U S A (2002) 3.55
Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn (2008) 2.30
Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet (2002) 2.17
Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement. Proc Natl Acad Sci U S A (2001) 1.85
Carcinogen-specific induction of genetic instability. Proc Natl Acad Sci U S A (2001) 1.76
Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol (2003) 1.67
Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol (1998) 1.55
Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia. Am J Pathol (1996) 1.47
Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut (2002) 1.38
Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc Natl Acad Sci U S A (1999) 1.33
Hereditary colorectal cancer in the general population: from cancer registration to molecular diagnosis. Gut (1999) 1.19
In silico and in vivo splicing analysis of MLH1 and MSH2 missense mutations shows exon- and tissue-specific effects. BMC Genomics (2006) 1.08
Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry. Fam Cancer (2013) 1.03
Microsatellite instability, MMR gene expression and proliferation kinetics in colorectal cancer with famillial predisposition. World J Gastroenterol (2000) 0.98
Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues. Br J Cancer (1997) 0.91
The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer. J Mol Histol (2006) 0.91
Expression of the hMLH1 and hMSH2 proteins in normal tissues: relationship to cancer predisposition in hereditary non-polyposis colon cancer. Virchows Arch (2004) 0.89
Homozygosity of MSH2 c.1906G-->C germline mutation is associated with childhood colon cancer, astrocytoma and signs of Neurofibromatosis type I. Fam Cancer (2008) 0.84
Mismatch repair genes (hMLH1, hPMS1, hPMS2, GTBP/hMSH6, hMSH2) in the pathogenesis of hepatocellular carcinoma. World J Gastroenterol (2005) 0.83
Loss of MSH2 protein expression is a risk factor in early stage cervical cancer. J Clin Pathol (2007) 0.81
Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis. Fam Cancer (2016) 0.80
Comparison of the Mismatch Repair System between Primary and Metastatic Colorectal Cancers Using Immunohistochemistry. J Pathol Transl Med (2017) 0.78
Immunohistochemical analysis of expression and allelotype of mismatch repair genes (hMLH1 and hMSH2) in bladder cancer. Br J Cancer (2001) 0.77
hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer. Br J Cancer (1999) 0.77
Expression of hMSH2 protein of the human DNA mismatch repair system in oral lichen planus. Int J Med Sci (2004) 0.76
The Norwegian PMS2 founder mutation c.989-1G > T shows high penetrance of microsatellite instable cancers with normal immunohistochemistry. Hered Cancer Clin Pract (2014) 0.75
A histopathological and immunohistochemical analysis of ameloblastic fibrodentinoma. Case Rep Pathol (2013) 0.75
Clinical significance of mismatch repair genes immunohistochemical expression of complex endometrial hyperplasia. Obstet Gynecol Sci (2015) 0.75
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01
"A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum. Anal Biochem (1984) 66.58
Serial analysis of gene expression. Science (1995) 60.15
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
The transcriptional landscape of the mammalian genome. Science (2005) 37.63
Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer (1972) 35.74
Surfing the p53 network. Nature (2000) 35.36
p53 mutations in human cancers. Science (1991) 31.96
Preparative and analytical purification of DNA from agarose. Proc Natl Acad Sci U S A (1979) 27.20
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Lessons from hereditary colorectal cancer. Cell (1996) 25.73
Cell death: the significance of apoptosis. Int Rev Cytol (1980) 24.88
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Functional annotation of a full-length mouse cDNA collection. Nature (2001) 23.61
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80
Genetic instabilities in human cancers. Nature (1998) 22.76
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell (1992) 19.87
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (1980) 17.69
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40
Induction of apoptosis in fibroblasts by c-myc protein. Cell (1992) 16.95
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Linkage disequilibrium mapping in isolated founder populations: diastrophic dysplasia in Finland. Nat Genet (1992) 15.62
Clues to the pathogenesis of familial colorectal cancer. Science (1993) 14.52
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (1995) 13.15
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
Genetic instability in colorectal cancers. Nature (1997) 12.51
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (1989) 11.53
Identification of FAP locus genes from chromosome 5q21. Science (1991) 11.41
A model for p53-induced apoptosis. Nature (1997) 11.38
Characterization of the yeast transcriptome. Cell (1997) 11.33
Telomere reduction in human colorectal carcinoma and with ageing. Nature (1990) 11.24
Mutations of mitotic checkpoint genes in human cancers. Nature (1998) 11.20
Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 11.18
Genes expressed in human tumor endothelium. Science (2000) 10.75
Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (1993) 10.72
Digital PCR. Proc Natl Acad Sci U S A (1999) 10.54
A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature (1998) 10.35
Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science (1992) 10.12
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Gene expression profiles in normal and cancer cells. Science (1997) 9.65
APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50
Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 9.28
Prevalence of ras gene mutations in human colorectal cancers. Nature (1987) 9.23
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature (1995) 9.03
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res (1994) 9.00
A public database for gene expression in human cancers. Cancer Res (1999) 8.81
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med (1998) 8.47
A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell (1996) 8.41
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet (1994) 8.34
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol (1983) 8.24
PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell (2001) 7.95
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (1993) 7.90
p53 function and dysfunction. Cell (1992) 7.73
Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest (1989) 7.60
14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell (1997) 7.20
Association of the APC tumor suppressor protein with catenins. Science (1993) 7.17
Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A (1987) 7.12